Literature DB >> 15537058

Technology evaluation: EMD-273063, EMD Lexigen.

Ion Niculescu-Duvaz1.   

Abstract

EMD-273063 is an antibody/cytokine fusion protein comprised of a humanized version of the murine anti-GD2 antibody 14.18 coupled to two molecules of IL-2. It is being developed by EMD Lexigen Research Center Corp (a subsidiary of Merck KGaA) and its sister company, EMD Pharmaceuticals Inc, for the potential treatment of neuroblastoma and melanoma, for which it is in preclinical and phase I clinical trials, respectively.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15537058

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  3 in total

1.  Human and murine IL2 receptors differentially respond to the human-IL2 component of immunocytokines.

Authors:  Zulmarie Perez Horta; Swetha Saseedhar; Alexander L Rakhmilevich; Lakeesha Carmichael; Jacquelyn A Hank; Margaret Boyden; Stephen D Gillies; Paul M Sondel
Journal:  Oncoimmunology       Date:  2018-05-07       Impact factor: 8.110

Review 2.  Pharmacokinetics of recombinant bifunctional fusion proteins.

Authors:  Xiaoying Chen; Jennica L Zaro; Wei-Chiang Shen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-03-20       Impact factor: 4.481

Review 3.  Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapy.

Authors:  Zulmarie Perez Horta; Jacob L Goldberg; Paul M Sondel
Journal:  Immunotherapy       Date:  2016-09       Impact factor: 4.196
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.